| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study.
|
Gastroenterology
|
2010
|
7.86
|
|
2
|
Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras.
|
Proc Natl Acad Sci U S A
|
2006
|
6.87
|
|
3
|
A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt.
|
Liver Int
|
2011
|
3.69
|
|
4
|
Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C.
|
J Hepatol
|
2009
|
3.28
|
|
5
|
A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel.
|
Liver Int
|
2011
|
2.77
|
|
6
|
Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection.
|
J Infect Dis
|
2006
|
2.55
|
|
7
|
IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection.
|
Hepatology
|
2006
|
2.54
|
|
8
|
Pioglitazone in chronic hepatitis C not responding to pegylated interferon-alpha and ribavirin.
|
J Hepatol
|
2008
|
2.28
|
|
9
|
Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data.
|
Gastroenterology
|
2006
|
2.26
|
|
10
|
IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction.
|
J Exp Med
|
2013
|
2.24
|
|
11
|
IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes.
|
Hepatology
|
2011
|
2.11
|
|
12
|
Enhanced B-cell differentiation and reduced proliferative capacity in chronic hepatitis C and chronic hepatitis B virus infections.
|
J Hepatol
|
2010
|
2.03
|
|
13
|
Barriers to interferon-alpha therapy are higher in intravenous drug users than in other patients with acute hepatitis C.
|
J Hepatol
|
2005
|
2.00
|
|
14
|
The global health burden of hepatitis C virus infection.
|
Liver Int
|
2011
|
1.80
|
|
15
|
Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms.
|
PLoS One
|
2011
|
1.69
|
|
16
|
Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C.
|
Hepatology
|
2010
|
1.61
|
|
17
|
Hepatitis C virus induces proteolytic cleavage of sterol regulatory element binding proteins and stimulates their phosphorylation via oxidative stress.
|
J Virol
|
2007
|
1.61
|
|
18
|
The homeostasis model assessment of the insulin resistance score is not predictive of a sustained virological response in chronic hepatitis C patients.
|
Liver Int
|
2010
|
1.51
|
|
19
|
The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanisms.
|
Hepatology
|
2007
|
1.50
|
|
20
|
An in vitro model of hepatitis C virus genotype 3a-associated triglycerides accumulation.
|
J Hepatol
|
2005
|
1.46
|
|
21
|
Homeostasis model assessment of insulin resistance does not seem to predict response to telaprevir in chronic hepatitis C in the REALIZE trial.
|
Hepatology
|
2013
|
1.41
|
|
22
|
IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional study.
|
PLoS Med
|
2011
|
1.36
|
|
23
|
Prevalence and challenges of liver diseases in patients with chronic hepatitis C virus infection.
|
Clin Gastroenterol Hepatol
|
2010
|
1.35
|
|
24
|
Nonalcoholic fatty liver disease in lean individuals in the United States.
|
Medicine (Baltimore)
|
2012
|
1.31
|
|
25
|
Trends and projections of hepatitis C virus epidemiology in Latin America.
|
Liver Int
|
2011
|
1.31
|
|
26
|
International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C.
|
J Hepatol
|
2005
|
1.30
|
|
27
|
Is genotype 3 of the hepatitis C virus the new villain?
|
Hepatology
|
2014
|
1.29
|
|
28
|
Cohort Profile: the Swiss Hepatitis C Cohort Study (SCCS).
|
Int J Epidemiol
|
2007
|
1.28
|
|
29
|
Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3.
|
J Hepatol
|
2007
|
1.23
|
|
30
|
The interaction of metabolic factors with HCV infection: does it matter?
|
J Hepatol
|
2012
|
1.22
|
|
31
|
Identification of common synaptic inputs to motor neurons from the rectified electromyogram.
|
J Physiol
|
2013
|
1.22
|
|
32
|
Viral genotype-specific role of PNPLA3, PPARG, MTTP, and IL28B in hepatitis C virus-associated steatosis.
|
J Hepatol
|
2011
|
1.19
|
|
33
|
Experimental analysis of accuracy in the identification of motor unit spike trains from high-density surface EMG.
|
IEEE Trans Neural Syst Rehabil Eng
|
2010
|
1.18
|
|
34
|
Monocyte chemoattractant protein-1 secreted by adipose tissue induces direct lipid accumulation in hepatocytes.
|
Hepatology
|
2008
|
1.13
|
|
35
|
Post-load insulin resistance does not predict virological response to treatment of chronic hepatitis C patients without the metabolic syndrome.
|
Dig Liver Dis
|
2012
|
1.10
|
|
36
|
Antigenic relevance of F protein in chronic hepatitis C virus infection.
|
Hepatology
|
2004
|
1.10
|
|
37
|
Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection.
|
Gastroenterology
|
2012
|
1.09
|
|
38
|
Applying a system approach to forecast the total hepatitis C virus-infected population size: model validation using US data.
|
Liver Int
|
2011
|
1.06
|
|
39
|
HCV-specific T-cell response in relation to viral kinetics and treatment outcome (DITTO-HCV project).
|
Gastroenterology
|
2007
|
1.06
|
|
40
|
Virus-induced over-expression of protein phosphatase 2A inhibits insulin signalling in chronic hepatitis C.
|
J Hepatol
|
2008
|
1.06
|
|
41
|
A genetic validation study reveals a role of vitamin D metabolism in the response to interferon-alfa-based therapy of chronic hepatitis C.
|
PLoS One
|
2012
|
1.05
|
|
42
|
Hepatitis D virus: an update.
|
Liver Int
|
2010
|
1.04
|
|
43
|
Hepatitis delta virus inhibits alpha interferon signaling.
|
Hepatology
|
2009
|
1.03
|
|
44
|
Amplitude cancellation of motor-unit action potentials in the surface electromyogram can be estimated with spike-triggered averaging.
|
J Neurophysiol
|
2008
|
1.01
|
|
45
|
Motor unit recruitment strategies and muscle properties determine the influence of synaptic noise on force steadiness.
|
J Neurophysiol
|
2012
|
1.01
|
|
46
|
Accessing the neural drive to muscle and translation to neurorehabilitation technologies.
|
IEEE Rev Biomed Eng
|
2012
|
0.99
|
|
47
|
Oral lichen planus pathogenesis: A role for the HCV-specific cellular immune response.
|
Hepatology
|
2002
|
0.98
|
|
48
|
Genetic analyses reveal a role for vitamin D insufficiency in HCV-associated hepatocellular carcinoma development.
|
PLoS One
|
2013
|
0.97
|
|
49
|
The hepatitis C virus core protein indirectly induces alpha-smooth muscle actin expression in hepatic stellate cells via interleukin-8.
|
J Hepatol
|
2010
|
0.96
|
|
50
|
Expression of Hepatocyte Growth Factor (HGF) and its Receptor (MET) in Medullary Carcinoma of the Thyroid.
|
Endocr Pathol
|
2000
|
0.96
|
|
51
|
Detecting the unique representation of motor-unit action potentials in the surface electromyogram.
|
J Neurophysiol
|
2008
|
0.95
|
|
52
|
Down-regulation of phosphatase and tensin homolog by hepatitis C virus core 3a in hepatocytes triggers the formation of large lipid droplets.
|
Hepatology
|
2011
|
0.95
|
|
53
|
Spatial correlation of high density EMG signals provides features robust to electrode number and shift in pattern recognition for myocontrol.
|
IEEE Trans Neural Syst Rehabil Eng
|
2014
|
0.95
|
|
54
|
Hepatitis C virus infection: molecular pathways to steatosis, insulin resistance and oxidative stress.
|
Viruses
|
2009
|
0.94
|
|
55
|
Statins may protect against hepatocellular carcinoma development in patients infected with hepatitis C virus, but what are the mechanisms?
|
J Clin Oncol
|
2013
|
0.94
|
|
56
|
Connective tissue growth factor, steatosis and fibrosis in patients with chronic hepatitis C.
|
Liver Int
|
2007
|
0.92
|
|
57
|
Hepatitis C virus and liver steatosis: is it the virus? Yes it is, but not always.
|
Hepatology
|
2002
|
0.91
|
|
58
|
Common synaptic input to motor neurons, motor unit synchronization, and force control.
|
Exerc Sport Sci Rev
|
2015
|
0.91
|
|
59
|
Serum ferritin levels are associated with a distinct phenotype of chronic hepatitis C poorly responding to pegylated interferon-alpha and ribavirin therapy.
|
Hepatology
|
2012
|
0.90
|
|
60
|
Acute and chronic hepatitis: Working Group report of the second World Congress of Pediatric Gastroenterology, Hepatology, and Nutrition.
|
J Pediatr Gastroenterol Nutr
|
2004
|
0.89
|
|
61
|
Impaired hepatic mitochondrial oxidation using the 13C-methionine breath test in patients with macrovesicular steatosis and patients with cirrhosis.
|
Med Sci Monit
|
2003
|
0.87
|
|
62
|
Comparative genetic analyses point to HCP5 as susceptibility locus for HCV-associated hepatocellular carcinoma.
|
J Hepatol
|
2013
|
0.87
|
|
63
|
Hepatitis E virus: a zoonosis adapting to humans.
|
J Antimicrob Chemother
|
2010
|
0.86
|
|
64
|
Impact of soluble CD26 on treatment outcome and hepatitis C virus-specific T cells in chronic hepatitis C virus genotype 1 infection.
|
PLoS One
|
2013
|
0.86
|
|
65
|
Elderly age is not a negative predictive factor for virological response to therapy with pegylated interferon-α and ribavirin in chronic hepatitis C virus patients.
|
Liver Int
|
2013
|
0.86
|
|
66
|
High-density surface EMG decomposition allows for recording of motor unit discharge from proximal and distal flexion synergy muscles simultaneously in individuals with stroke.
|
Conf Proc IEEE Eng Med Biol Soc
|
2014
|
0.85
|
|
67
|
Spatial distribution of surface action potentials generated by individual motor units in the human biceps brachii muscle.
|
J Electromyogr Kinesiol
|
2013
|
0.85
|
|
68
|
Lack of evidence for ribavirin-induced bone loss.
|
Hepatology
|
2002
|
0.84
|
|
69
|
In vitro antiviral activity of SCH446211 (SCH6), a novel inhibitor of the hepatitis C virus NS3 serine protease.
|
J Antimicrob Chemother
|
2006
|
0.84
|
|
70
|
Long-term effects of treatment and response in patients with chronic hepatitis C on quality of life. An international, multicenter, randomized, controlled study.
|
BMC Gastroenterol
|
2012
|
0.84
|
|
71
|
Gene expression profile of Huh-7 cells expressing hepatitis C virus genotype 1b or 3a core proteins.
|
Liver Int
|
2008
|
0.84
|
|
72
|
Hepatitis B and C in Switzerland - healthcare provider initiated testing for chronic hepatitis B and C infection.
|
Swiss Med Wkly
|
2013
|
0.84
|
|
73
|
High-density EMG E-textile systems for the control of active prostheses.
|
Conf Proc IEEE Eng Med Biol Soc
|
2010
|
0.83
|
|
74
|
Low-frequency oscillations of the neural drive to the muscle are increased with experimental muscle pain.
|
J Neurophysiol
|
2011
|
0.83
|
|
75
|
Neural correlates of task-related changes in physiological tremor.
|
J Neurophysiol
|
2013
|
0.83
|
|
76
|
Hepatitis C virus and liver steatosis: when fat is not beautiful.
|
J Hepatol
|
2004
|
0.82
|
|
77
|
Hepatocellular adenoma and polycystic ovary syndrome.
|
Liver Int
|
2003
|
0.82
|
|
78
|
Alcohol is an important co-factor for both steatosis and fibrosis in Northern Italian patients with chronic hepatitis C.
|
J Hepatol
|
2004
|
0.81
|
|
79
|
Does telaprevir possess a direct antidiabetic effect?
|
Liver Int
|
2014
|
0.81
|
|
80
|
Molecular evidence that the hepatitis C virus replicates in the oral mucosa.
|
J Hepatol
|
2002
|
0.81
|
|
81
|
PTEN protein phosphatase activity regulates hepatitis C virus secretion through modulation of cholesterol metabolism.
|
J Hepatol
|
2013
|
0.81
|
|
82
|
Hepatitis C virus: the viral way to fatty liver.
|
J Hepatol
|
2007
|
0.80
|
|
83
|
Lack of in vivo blockade of Fas- and TNFR1-mediated hepatocyte apoptosis by the hepatitis C virus.
|
J Pathol
|
2002
|
0.79
|
|
84
|
Treatment of hepatitis C in HCV mono-infected and in HIV-HCV co-infected patients: an open-labelled comparison study.
|
Swiss Med Wkly
|
2010
|
0.79
|
|
85
|
Correction of insulin resistance in chronic hepatitis C patients not responding to the standard of care: more questions than answers.
|
J Hepatol
|
2009
|
0.79
|
|
86
|
Immunological and virological effects of ribavirin in hepatitis C after liver transplantation.
|
Transplantation
|
2002
|
0.79
|
|
87
|
STAT6 promotes bi-directional modulation of PKM2 in liver and adipose inflammatory cells in rosiglitazone-treated mice.
|
Sci Rep
|
2013
|
0.79
|
|
88
|
Steatosis in chronic hepatitis C: friend or foe?
|
Liver Int
|
2008
|
0.79
|
|
89
|
Role of seipin in lipid droplet morphology and hepatitis C virus life cycle.
|
J Gen Virol
|
2013
|
0.79
|
|
90
|
Intrahepatic mRNA levels of SOCS1 and SOCS3 are associated with cirrhosis but do not predict virological response to therapy in chronic hepatitis C.
|
Liver Int
|
2012
|
0.79
|
|
91
|
Hepatitis C viral kinetics in plasma and peripheral blood mononuclear cells during pegylated interferon-alpha2a/ribavirin therapy.
|
J Hepatol
|
2008
|
0.78
|
|
92
|
Ribavirin/interferon-alpha sequential treatment of recurrent hepatitis C after liver transplantation.
|
Transpl Int
|
2004
|
0.78
|
|
93
|
IL28B polymorphisms do not predict response to therapy in chronic hepatitis C with HCV genotype 5.
|
Gut
|
2012
|
0.78
|
|
94
|
Real-time multiplex PCR assay to quantify hepatitis C virus RNA in peripheral blood mononuclear cells.
|
J Virol Methods
|
2005
|
0.78
|
|
95
|
ABO incompatible kidney transplantation from an anti-hepatitis C virus antibody-positive RNA-negative donor into an anti-hepatitis C virus antibody-negative recipient.
|
Transpl Int
|
2014
|
0.78
|
|
96
|
The new EASL guidelines for the management of chronic hepatitis B infection adapted for Swiss physicians.
|
Swiss Med Wkly
|
2010
|
0.77
|
|
97
|
The impact of obesity and metabolic syndrome on chronic hepatitis C.
|
Clin Liver Dis
|
2013
|
0.77
|
|
98
|
Effects of hepatitis C virus on suppressor of cytokine signaling mRNA levels: comparison between different genotypes and core protein sequence analysis.
|
J Med Virol
|
2011
|
0.77
|
|
99
|
Chronic hepatitis E in the immunosuppressed: a new source of trouble?
|
J Hepatol
|
2008
|
0.77
|
|
100
|
Estimation of muscle fiber conduction velocity with a spectral multidip approach.
|
IEEE Trans Biomed Eng
|
2007
|
0.76
|
|
101
|
Reply from Dario Farina, Francesco Negro and Ning Jiang.
|
J Physiol
|
2014
|
0.76
|
|
102
|
Optimized vaccination regimen linked to exhaustive screening approaches identifies 2 novel HLA-B7 restricted epitopes within hepatitis C virus NS3 protein.
|
Microbes Infect
|
2006
|
0.76
|
|
103
|
Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma.
|
Swiss Med Wkly
|
2012
|
0.76
|
|
104
|
Current understanding of insulin resistance in hepatitis C.
|
Expert Rev Gastroenterol Hepatol
|
2011
|
0.76
|
|
105
|
Hepatitis C virus genotype 1 associated with massive steatosis of the liver and hypo-beta-lipoproteinemia.
|
J Hepatol
|
2004
|
0.75
|
|
106
|
Impaired regulation post-stroke of motor unit firing behavior during volitional relaxation of knee extensor torque assessed using high density surface EMG decomposition.
|
Conf Proc IEEE Eng Med Biol Soc
|
2015
|
0.75
|
|
107
|
Hepatitis C virus and gastric mucosa-associated lymphoid tissue: has proteus reached the stomach?
|
J Clin Gastroenterol
|
2004
|
0.75
|
|
108
|
Properties of the motor unit action potential shape in proximal and distal muscles of the upper limb in healthy and post-stroke individuals.
|
Conf Proc IEEE Eng Med Biol Soc
|
2016
|
0.75
|
|
109
|
The paradox of Epstein-Barr virus-associated hepatitis.
|
J Hepatol
|
2006
|
0.75
|
|
110
|
Magnetic susceptibility of strongly interacting matter across the deconfinement transition.
|
Phys Rev Lett
|
2013
|
0.75
|
|
111
|
Susceptibility of the QCD vacuum to CP-odd electromagnetic background fields.
|
Phys Rev Lett
|
2013
|
0.75
|
|
112
|
[Hepatitis D: forgotten but not gone].
|
Rev Med Suisse
|
2010
|
0.75
|
|
113
|
Theoretical Model and Experimental Validation of the estimated proportions of common and independent input to motor neurons.
|
Conf Proc IEEE Eng Med Biol Soc
|
2015
|
0.75
|
|
114
|
[Hepatitis C and insulin resistance].
|
Rev Med Suisse
|
2008
|
0.75
|
|
115
|
[New treatments for hepatitis C, which targets, what timeline?].
|
Rev Med Suisse
|
2011
|
0.75
|
|
116
|
[Our friend...coffee].
|
Rev Med Suisse
|
2007
|
0.75
|
|
117
|
How should we treat recurrent hepatitis C after liver transplantation?
|
J Hepatol
|
2005
|
0.75
|
|
118
|
[New aspects of HEV infection].
|
Rev Med Suisse
|
2008
|
0.75
|
|
119
|
The tragedy of (unpublished) errors.
|
Nat Clin Pract Gastroenterol Hepatol
|
2006
|
0.75
|
|
120
|
Power spectrum of the rectified EMG: influence of motor unit action potential shapes.
|
Conf Proc IEEE Eng Med Biol Soc
|
2014
|
0.75
|
|
121
|
[Dermatitis associated with the treatment of chronic hepatitis C].
|
Rev Med Suisse
|
2005
|
0.75
|
|
122
|
Immunohistochemical detection of hepatitis delta antigen.
|
Methods Mol Med
|
2004
|
0.75
|
|
123
|
Editor's Note.
|
Liver Int
|
2017
|
0.75
|
|
124
|
Corrigendum: reduced IFNλ4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes.
|
Nat Commun
|
2015
|
0.75
|
|
125
|
The 4,977-base pair common deletion of mitochondrial DNA is not associated with steatosis in chronic hepatitis C patients.
|
Hepatology
|
2002
|
0.75
|
|
126
|
[Extra-hepatic morbidity and mortality related to hepatitis C virus infection].
|
Rev Med Suisse
|
2014
|
0.75
|
|
127
|
θ dependence of the deconfinement temperature in Yang-Mills theories.
|
Phys Rev Lett
|
2012
|
0.75
|
|
128
|
Differential Motor Unit Changes after Endurance or High-Intensity Interval Training.
|
Med Sci Sports Exerc
|
2017
|
0.75
|